Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC. Verra N, et al. Among authors: groenewegen g. Br J Cancer. 2003 May 6;88(9):1346-51. doi: 10.1038/sj.bjc.6600915. Br J Cancer. 2003. PMID: 12778059 Free PMC article. Clinical Trial.
Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, De Mulder PH. van Herpen CM, et al. Among authors: groenewegen g. Br J Cancer. 2000 Feb;82(4):772-6. doi: 10.1054/bjoc.1999.0997. Br J Cancer. 2000. PMID: 10732744 Free PMC article. Clinical Trial.
Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha.
Groenewegen G, Bloem A, De Gast GC. Groenewegen G, et al. Cancer Immunol Immunother. 2002 Dec;51(11-12):630-6. doi: 10.1007/s00262-002-0323-1. Epub 2002 Oct 15. Cancer Immunol Immunother. 2002. PMID: 12439608 Free PMC article. Clinical Trial.
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.
Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C, Stockmeyer B, Becker W, Eisenhut M, Steininger H, Deo YM, Blijham GH, Kalden JR, van de Winkel JG, Gramatzki M. Repp R, et al. Among authors: groenewegen g. Br J Cancer. 2003 Dec 15;89(12):2234-43. doi: 10.1038/sj.bjc.6601367. Br J Cancer. 2003. PMID: 14676800 Free PMC article. Clinical Trial.
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
Kerbusch T, Groenewegen G, Mathôt RA, Herben VM, ten Bokkel Huinink WW, Swart M, Ambaum B, Rosing H, Jansen S, Voest EE, Beijnen JH, Schellens JH. Kerbusch T, et al. Among authors: groenewegen g. Br J Cancer. 2004 Jun 14;90(12):2268-77. doi: 10.1038/sj.bjc.6601861. Br J Cancer. 2004. PMID: 15150579 Free PMC article. Clinical Trial.
Risk of diabetes after para-aortic radiation for testicular cancer.
Groot HJ, Gietema JA, Aleman BMP, Incrocci L, de Wit R, Witjes JA, Groenewegen G, de Brouwer P, Meijer OWM, Hulshof MCCM, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, van den Bergh ACM, Kerst JM, van den Belt-Dusebout AW, Lubberts S, Jóźwiak K, Horenblas S, van Leeuwen FE, Schaapveld M. Groot HJ, et al. Among authors: groenewegen g. Br J Cancer. 2018 Oct;119(7):901-907. doi: 10.1038/s41416-018-0248-x. Epub 2018 Oct 9. Br J Cancer. 2018. PMID: 30297773 Free PMC article.
66 results